Öz

Carnitine palmitoyltransferase II (CPT-II) deficiency is an autosomal recessive inherited metabolic disorder and represents the most common genetic cause of recurrent rhabdomyolysis in adulthood. The clinical course is characterized by episodic attacks precipitated by intense physical exertion, infections, psychological stress, or other physical and emotional stressors. Although avoidance or early recognition of triggering factors plays a critical role in prognosis, many patients continue to experience recurrent episodes of rhabdomyolysis. Management primarily focuses on elimination of precipitating factors and meticulous correction of fluid and electrolyte imbalances. Prompt recognition of CPT-II deficiency and rapid identification and management of rhabdomyolysis triggers are essential for preventing life-threatening complications.

We report the clinical characteristics, therapeutic interventions, and outcome of a 31-year-old male patient with known CPT-II deficiency. The patient presented with dyspnea and generalized muscle weakness following an infectious episode. Laboratory evaluation revealed markedly elevated creatine kinase levels, and rhabdomyolysis secondary to CPT-II deficiency was diagnosed. The patient received supportive management, including intravenous fluid therapy for electrolyte stabilization, close monitoring in the intensive care unit, and treatment with triheptanoin. His symptoms improved gradually, and he was discharged in stable condition with recommendations emphasizing avoidance of known triggers and long-term disease management.

This report aims to underscore the importance of early diagnosis and timely therapeutic intervention in the management of CPT-II deficiency.

Anahtar Kelimeler: CPT-II deficiency, rhabdomyolysis, respiratory failure, triheptanoin

Referanslar

  1. Lehmann D, Motlagh L, Robaa D, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: a review of enzymatic controversy and clinical features. Int J Mol Sci. 2017;18:82. https://doi.org/10.3390/ijms18010082
  2. Avila-Smirnow D, Boutron A, Beytía-Reyes MLÁ, et al. Carnitine palmitoyltransferase type 2 deficiency: novel mutation in a Native South American family with whole-body muscle magnetic resonance imaging findings: two case reports. J Med Case Rep. 2018;12:249. https://doi.org/10.1186/s13256-018-1702-3
  3. Joshi PR, Zierz S. Muscle carnitine palmitoyltransferase II (CPT II) deficiency: a conceptual approach. Molecules. 2020;25:1784. https://doi.org/10.3390/molecules25081784
  4. Çakar NE, Gör Z, Yeşil G. Cause of recurrent rhabdomyolysis, carnitine palmitoyltransferase II deficiency and novel pathogenic mutation. Ideggyogy Sz. 2021;74:135-8. https://doi.org/10.18071/isz.74.0135
  5. Ivin N, Della Torre V, Sanders F, Youngman M. Rhabdomyolysis caused by carnitine palmitoyltransferase 2 deficiency: a case report and systematic review of the literature. J Intensive Care Soc. 2020;21:165-73. https://doi.org/10.1177/1751143719889766
  6. Gillingham MB, Heitner SB, Martin J, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40:831-43. https://doi.org/10.1007/s10545-017-0085-8
  7. Ambrose A, Sheehan M, Bahl S, et al. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic. Orphanet J Rare Dis. 2022;17:360. https://doi.org/10.1186/s13023-022-02512-5
  8. Lu CH, Yang CF, Chen YR, Chen YJ, Lu YH, Niu DM. Recurrent rhabdomyolysis caused by palmitoyltransferase II (CPT-2) deficiency but complete normal acylcarnitine profile: a patient presentation and review of the literature. Mol Genet Metab Rep. 2024;41:101151. https://doi.org/10.1016/j.ymgmr.2024.101151
  9. Hogan KJ, Vladutiu GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg. 2009;109:1070-2. https://doi.org/10.1213/ane.0b013e3181ad63b4
  10. Yu HK, Ok SH, Kim S, Sohn JT. Anesthetic management of patients with carnitine deficiency or a defect of the fatty acid β-oxidation pathway: a narrative review. Medicine (Baltimore). 2022;101:e28853. https://doi.org/10.1097/MD.0000000000028853
  11. Wong GK, Crawford MW. Carnitine deficiency increases susceptibility to bupivacaine-induced cardiotoxicity in rats. Anesthesiology. 2011;114:1417-24. https://doi.org/10.1097/ALN.0b013e31821a8d46
  12. Kido J, Matsumoto S, Ito T, et al. Physical, cognitive, and social status of patients with urea cycle disorders in Japan. Mol Genet Metab Rep. 2021;27:100724. https://doi.org/10.1016/j.ymgmr.2021.100724
  13. Blah N, Sudrié-Arnaud B, Torre S, Marret S, Bekri S, Tebani A. Acute respiratory infection unveiling CPT II deficiency. Int J Mol Sci. 2018;19:2950. https://doi.org/10.3390/ijms19102950
  14. Angelini C, Pennisi E, Missaglia S, Tavian D. Metabolic lipid muscle disorders: biomarkers and treatment. Ther Adv Neurol Disord. 2019;12:1756286419843359. https://doi.org/10.1177/1756286419843359
  15. Mccormick BJ, Chirila RM. Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature. Rom J Intern Med. 2021;59:420-4. https://doi.org/10.2478/rjim-2021-0021
  16. Gentili A, Iannella E, Masciopinto F, Latrofa ME, Giuntoli L, Baroncini S. Rhabdomyolysis and respiratory failure: rare presentation of carnitine palmityl-transferase II deficiency. Minerva Anestesiol. 2008;74:205-8.
  17. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med. 2003;168:10-48. https://doi.org/10.1164/rccm.2206020
  18. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62-72. https://doi.org/10.1056/NEJMra0801327
  19. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25:495-520. https://doi.org/10.1016/j.mam.2004.06.004

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
Yeniay H, Yarar V, Kılınç G, Özgüngör Y, Çakırgöz M. Carnitine palmitoyltransferase II deficiency: a case of post-infectious rhabdomyolysis and respiratory failure. Turk J Intensive Care. 2026;24(3):209-215. https://doi.org/10.63729/TJIC.2026.705